Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays

Human Pathology

Volumn 45, Issue 11, 2014, Pages 2281-2293

  Fisher, Kevin E ^a   Cohen, Cynthia ^a   Siddiqui, Momin T ^a   Palma, John F ^b   Lipford, Edward H ^c   Longshore, John W ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c Carolinas Pathology Group   (United States)

Author keywords

BRAF; Comparison; Criteria; Immunohistochemistry; Melanoma; Molecular; V600E

Indexed keywords

B RAF KINASE; B RAF KINASE V600E; EPITOPE; MELANIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN;

ARTICLE; CANCER PATIENT; CANCER TISSUE; CONSENSUS; CONTROLLED STUDY; CROSS REACTION; FALSE NEGATIVE RESULT; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LARGE CORE NEEDLE BIOPSY; MELANOMA; METASTASIS; METASTATIC MELANOMA; MOLECULAR DIAGNOSIS; PATHOLOGIST; PIGMENTATION; PREDICTIVE VALUE; PYROSEQUENCING; REPRODUCIBILITY; RETROSPECTIVE STUDY; SCREENING TEST; TISSUE NECROSIS; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SKIN TUMOR;

DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS;

EID: 84908318730     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.07.014     Document Type: Article

References (34)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
3. J.A. Curtin, J. Fridlyand, and T. Kageshita Distinct sets of genetic alterations in melanoma NEJM 353 2005 2135 2147
4. J.S. Inamura, K.I. Gordo, and A.C. Fraga Junior Analysis of the BRAF V600E mutation in primary cutaneous melanoma Genet Mol Res 2 2014 2840 2848
5. K. DeCarlo, S. Yang, A. Emley, N. Wajapeyee, M. Green, and M. Mahalingam Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7 - challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol 41 2010 886 894
6. C.M. Lovly, K.B. Dahlman, and L.E. Fohn Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials PLoS One 7 2012 e35309
7. Distribution of somatic mutation in BRAF COSMIC Database v68, release date February 4, 2014, Sanger Institute http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ [Accessed May 14, 2014]
8. G.A. McArthur, P.B. Chapman, and C. Robert Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Lancet Oncol 15 2014 323 332
9. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation NEJM 364 2011 2507 2516
10. A. Hauschild, J.J. Grob, and L.V. Demidov Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
11. S. Anderson, K.J. Bloom, and D.U. Vallera Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma Arch Pathol Lab Med 136 2012 1385 1391
12. H. Halait, K. Demartin, and S. Shah Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma Diagn Mol Pathol 21 2012 1 8
13. D. Capper, M. Preusser, and A. Habel Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody Acta Neuropathol 122 2011 11 19
14. G.V. Long, J.S. Wilmott, and D. Capper Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma Am J Surg Pathol 37 2013 61 65
15. C. Marin, A. Beauchet, and D. Capper Detection of BRAF p.V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility Arch Pathol Lab Med 138 2014 71 75
16. Q. Chen, C. Xia, and Y. Deng Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients Tumor Biol 35 2014 5727 5733
17. J.K. Feller, S. Yang, and M. Mahalingam Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma Mod Pathol 26 2013 414 420
18. M. Margulies, M. Egholm, and W.E. Altman Genome sequencing in microfabricated high-density picolitre reactors Nature 437 2005 376 380
19. A.G. Hadd, J. Houghton, and A. Choudhary Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens J Mol Diagn 15 2013 234 247
20. K.E. Fisher, S.G. Neill, L. Ehsani, S.A. Caltharp, M.T. Siddiqui, and C. Cohen Immunohistochemical investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies Appl Immunohistochem Mol Morphol 2014 10.1097/PAI.0b013e3182a2f75f
21. K.E. Fisher, J.C. Jani, and S.B. Fisher Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma J Surg Res 185 2013 217 224
22. S.B. Fisher, K.E. Fisher, and S.H. Patel Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy Cancer 119 2013 454 462
23. M.H. Squires III, S.B. Fisher, and K.E. Fisher Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma Cancer 119 2013 3242 3250
24. C.M. van der Loos Chromogens in multiple immunohistochemical staining used for visual assessment and spectral imaging: the colorful future J Histotechnol 33 2010 31 40
25. M.V. Pearlstein, D.C. Zedek, and D.W. Ollila Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma J Cutan Pathol 2014 10.1111/cup.12364
26. C.A. Routhier, M.C. Mochel, K. Lynch, D. Dias-Santagata, D.N. Louis, and M.P. Hoang Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas Hum Pathol 44 2013 2563 2570
27. J. Zagzag, A. Pollack, and L. Dultz Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma Surgery 154 2013 1199 1204
28. S.F. Kuan, S. Navina, K.L. Cressman, and R.K. Pai Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization Hum Pathol 45 2014 464 472
29. M. Yancovitz, A. Litterman, and J. Yoon Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma PLoS One 7 2012 e29336
30. A.M. Menzies, T. Lum, and J.S. Wilmott Intrapatient homogeneity of BRAFV600E expression in melanoma Am J Surg Pathol 38 2014 377 382
31. L. Boursault, V. Haddad, and B. Vergier Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing PLoS One 8 2013 e70826
32. J. Ruschoff, M. Dietel, and G. Baretton HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing Virchows Arch 457 2010 299 307
33. A.C. Wolff, M.E. Hammond, and D.G. Hicks Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 2013 3997 4013
34. C.M. Ida, J.A. Vrana, and F.J. Rodriguez Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma Acta Neuropathol Commun 1 2013 20